Education
About Us
Working with TipRanks
Follow Us
Corbus Pharmaceuticals (CRBP)
NASDAQ:CRBP
Total Valuation
Corbus Pharmaceuticals has a market cap or net worth of $73.88M. The enterprise value is -$2.39M.
Market Cap$73.88M
Enterprise Value-$2.39M
Share Statistics
Corbus Pharmaceuticals has 12.23M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding12.23M
Owned by Insiders31.09%
Owned by Instutions0.07%
Financial Efficiency
Corbus Pharmaceuticals’s return on equity (ROE) is -0.28 and return on invested capital (ROIC) is 0.00%.
Return on Equity (ROE)-28.23%
Return on Assets (ROA)-25.80%
Return on Invested Capital (ROIC)0.00%
Return on Capital Employed (ROCE)0.00%
Revenue Per Employee$0
Profits Per Employee-$1,436,027.536
Employee Count28
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Corbus Pharmaceuticals is -3.20. Corbus Pharmaceuticals’s PEG ratio is 0.05.
PE Ratio-3.20
PS Ratio0.00
PB Ratio0.90
Price to Fair Value0.90
Price to FCF-3.08
Price to Operating Cash Flow-3.08
PEG Ratio0.05
Income Statement
In the last 12 months, Corbus Pharmaceuticals had revenue of $0.00 and earned -$40.21M in profits. Earnings per share was -$8.02.
Revenue$0.00
Gross Profit-$351.69K
Operating Income-$48.72M
Pretax Income-$40.21M
Net Income-$40.21M
EBITDA-41.26M
Earnings Per Share (EPS)-8.02
Cash Flow
In the last 12 months, operating cash flow was -$41.79M and capital expenditures $0.00, giving a free cash flow of -$41.79M billion.
Operating Cash Flow-$41.79M
Free Cash Flow-$41.79M
Free Cash Flow per Share-$3.42
Dividends & Yields
Corbus Pharmaceuticals pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-32.45%
Earnings Yield-31.22%
Stock Price Statistics
Beta1.59
52-Week Price Change-85.86%
50-Day Moving Average7.18
200-Day Moving Average25.29
Relative Strength Index (RSI)25.31
Average Volume (3m)218.74K
Important Dates
Corbus Pharmaceuticals upcoming earnings date is May 13, 2025, TBA.
Last Earnings DateMar 11, 2025
Next Earnings DateMay 13, 2025
Ex-Dividend Date―
Financial Position
Corbus Pharmaceuticals as a current ratio of 12.94, with Debt / Equity ratio of 0.02
Current Ratio12.94
Quick Ratio12.94
Debt to Market Cap0.03
Net Debt to EBITDA0.00
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Corbus Pharmaceuticals has paid $2.00 in taxes.
Income Tax$2.00
Effective Tax Rate0.00%
Enterprise Valuation
Corbus Pharmaceuticals EV to EBITDA ratio is 0.00, with an EV/FCF ratio of -2.75.
EV to Sales0.00
EV to EBITDA0.00
EV to Free Cash Flow-2.75
EV to Operating Cash Flow-2.75
Balance Sheet
Corbus Pharmaceuticals has $149.06M in cash and marketable securities with $3.24M in debt, giving a net cash position of -$145.82M billion.
Cash & Marketable Securities$149.06M
Total Debt$3.24M
Net Cash-$145.82M
Net Cash Per Share-$11.92
Tangible Book Value Per Share$13.05
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Corbus Pharmaceuticals is $53.63, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$53.63
Price Target Upside787.91%
Analyst ConsensusStrong Buy
Analyst Count9
Revenue Growth Forecast
EPS Growth Forecast64.71%